[Experience of Teraligen usage in pediatric psychiatry].
A V GoryunovO E SergeevaPublished in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2022)
The data of studies on the use of Teraligen in various fields of clinical medicine - neurology, dermatology, gastroenterology, anesthesiology and psychiatry are presented. According to studies conducted in psychiatry, Teraligen is a drug for the balanced treatment of anxiety-phobic, behavioral and sleep disorders in children, both within neurotic conditions and in the structure of autistic and schizophrenic spectrum disorders. Based on 100 case histories of children aged 3 to 16 years, the experience of using Teraligen as part of mono- and combination therapy at a dosage of 1.25 mg to 50 mg/day in the treatment of autism spectrum disorders ( n =31), psychotic disorders ( n =18), schizotypal disorders ( n =41), behavioral and emotional disorders on residual organic soil ( n =10). A good clinical effect of Teraligen has been shown in anxiety-phobic, affective, somatovegetative disorders and sleep disorders in all identified nosologies. Good tolerability of Teraligen, the possibility of its use as part of complex therapy and the almost complete absence of adverse events, indicating the softness and balance of the drug were noted.
Keyphrases
- combination therapy
- sleep quality
- autism spectrum disorder
- bipolar disorder
- machine learning
- young adults
- clinical trial
- emergency department
- stem cells
- depressive symptoms
- electronic health record
- mesenchymal stem cells
- open label
- attention deficit hyperactivity disorder
- replacement therapy
- working memory
- smoking cessation